Soluble thrombomodulin in preeclampsia: Systematic review and meta-analysis
- PMID: 40320160
- DOI: 10.1016/j.cca.2025.120323
Soluble thrombomodulin in preeclampsia: Systematic review and meta-analysis
Abstract
Preeclampsia (PE) is a severe pregnancy complication associated with endothelial dysfunction. Soluble thrombomodulin (sTM) is a biomarker of endothelial injury, but its role in PE remains unclear. Although previous studies suggest elevated sTM levels in PE, inconsistencies in study designs and diagnostic criteria have led to conflicting findings. Our study addresses this gap through a systematic review and meta-analysis using standardized effect sizes and predefined severity groups to clarify the association between sTM and PE. This review followed the Cochrane Handbook and PRISMA guidelines and was registered in PROSPERO (CRD42023456919). A comprehensive search was conducted in MEDLINE/PubMed, EMBASE, and Web of Science for observational studies evaluating sTM levels in PE and normotensive controls. Eligible studies included case-control and cohort designs measuring sTM in plasma or serum. Two reviewers independently conducted data extraction and risk of bias assessment (Newcastle-Ottawa Scale). A random-effects meta-analysis estimated the Standardized Mean Difference (SMD) and 95 % confidence intervals (CI). Of 285 screened studies, 26 met inclusion criteria, and 20 were included in the meta-analysis. sTM levels were significantly higher in PE (SMD = 0.91, 95 % CI 0.3 to 1.53; I2 = 94 %) with greater elevation in severe PE (SMD: 0.86, 95 % CI 0.55 to 1.16; I2 = 50 %) than mild PE (SMD: 0.57, 95 % CI 0.08 to 1.06; I2 = 82 %). High heterogeneity was observed, likely due to variations in inclusion criteria, measurement techniques, and diagnostic definitions. These findings support the potential of sTM as a biomarker for assessing PE severity. However, its clinical use remains limited by methodological heterogeneity and lack of standardized cutoff values. Further prospective studies are needed to validate its diagnostic and prognostic value and to enable its integration into clinical practice.
Keywords: Biomarker; Endothelial Dysfunction; Meta-Analysis; Preeclampsia; Soluble Thrombomodulin; Systematic Review.
Copyright © 2025 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Glycosylated fibronectin in preeclampsia: a systematic review and meta-analysis.BMC Pregnancy Childbirth. 2025 Feb 28;25(1):228. doi: 10.1186/s12884-025-07243-6. BMC Pregnancy Childbirth. 2025. PMID: 40022002 Free PMC article.
-
Altered release of thrombomodulin and HMGB1 in the placenta complicated with preeclampsia.Placenta. 2024 Mar 25;148:12-19. doi: 10.1016/j.placenta.2024.01.016. Epub 2024 Feb 1. Placenta. 2024. PMID: 38330539
-
The potential predictive value of miR-181 in women with preeclampsia: a systematic review and meta-analysis.BMC Pregnancy Childbirth. 2025 Apr 23;25(1):474. doi: 10.1186/s12884-025-07589-x. BMC Pregnancy Childbirth. 2025. PMID: 40269776 Free PMC article.
-
Association between circulating visfatin and pre-eclampsia: a systematic review and meta-analysis.J Matern Fetal Neonatal Med. 2022 Jul;35(13):2606-2618. doi: 10.1080/14767058.2020.1789581. Epub 2020 Jul 7. J Matern Fetal Neonatal Med. 2022. PMID: 32635792
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous